Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00723463 · ClinicalTrials.gov registry record · Early Phase 1
Determine if Apparent Diffusion Coefficient (ADC) Values Can Differentiate Tumors From Normal Tissue
A Early Phase 1 study of Brain Cancer and Neck Cancer, sponsored by University of Michigan.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 200
- Enrollment target
- 1
- Study location
NCT00723463 is a Early Phase 1 study of Brain Cancer and Neck Cancer that has completed, run by University of Michigan. The registered enrollment target is 200 participants, below the 503-participant average among 47 other Brain Cancer trials with a reported enrollment target (60% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00723463, a Early Phase 1 study of Brain Cancer and Neck Cancer, has completed, sponsored by University of Michigan.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 200 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to determine normal measurements (ADC values) from the head and neck of healthy volunteers using 3T MRI.
Conditions Studied
Interventions
- PROCEDURE 3T MRI scan
Study Locations (1)
Michigan
- University of Michigan Health System - Ann Arbor
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Start Date | 2006-06 |
| Est. Completion | 2016-07 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00723463
The ClinicalTrials.gov registry entry for NCT00723463 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 200 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 503-participant average among 47 other Brain Cancer trials with a reported enrollment target (60% lower). The listed sponsor is University of Michigan, which has 1,327 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Brain Cancer appearing as the primary indexed condition, and to 1 intervention - of which 3T MRI scan is the first listed.
NCT00723463 reports 1 study location spanning 1 distinct geographic area - top geographies include Michigan.
Frequently Asked Questions
What is clinical trial NCT00723463 about?
NCT00723463 is a clinical study titled "Determine if Apparent Diffusion Coefficient (ADC) Values Can Differentiate Tumors From Normal Tissue". The purpose of this study is to determine normal measurements (ADC values) from the head and neck of healthy volunteers using 3T MRI.
What is the current status of trial NCT00723463?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 200 participants. The study started on 2006-06. Estimated completion is 2016-07.
What conditions does trial NCT00723463 study?
This clinical trial studies the following conditions: Brain Cancer, Neck Cancer.
What interventions are being tested in trial NCT00723463?
The interventions under investigation include: 3T MRI scan (PROCEDURE).
Who is sponsoring clinical trial NCT00723463?
This trial is sponsored by University of Michigan, which has 1,327 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00723463 being conducted?
This trial has 1 study location across Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Brain Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
PET and MRI Imaging of Brain Tumors Using [18F]PARPi
COMPLETED · Early Phase 1
-
Super-selective Intra-arterial Repeated Infusion of Cetuximab for the Treatment of Newly Diagnosed Glioblastoma
RECRUITING · Phase 1
-
18F-Fluciclovine PET Amino Acid Evaluation of Brain Metastasis Treated With Stereotactic Radiosurgery
RECRUITING · Phase 1
-
Assess Use of 18F-Fluciclovine for Patients With Large Brain Metastases Treated With Staged Stereotactic Radiosurgery
RECRUITING · Phase 1
-
Adenovirus Mediated Suicide Gene Therapy With Radiotherapy in Progressive Astrocytoma.
RECRUITING · Phase 1
-
Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIII
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.